Summary: Nonlinear mixed effects models allow investigating individual differences in drug concentration profiles (pharmacokinetics) and responses. Pharmacogenetics focusses on the genetic component of this variability. Two tests often used to detect a gene effect on a pharmacokinetic parameter are i) the Wald test, assessing whether estimates for the gene effect are significantly different from 0 and ii) the likelihood ratio test comparing models with and without the genetic effect.
Introduction
Pharmacokinetics (PK) studies the time course of a drug in the body. Nonlinear mixed effects models (NLMEM) in the analysis of PK data allow integrating the knowledge accumulated on drug absorption, distribution, metabolism and elimination (ADME), to quantify the inter-individual variability with fewer samples per patient than standard non compartmental approaches. Pharmacogenetics (PG) studies the relationship between this inter-individual variability and variations in the DNA sequence of proteins involved in the ADME mechanisms of the drug.
In previous simulation studies, we have shown that a correction for type I error inflation was required for the two most commonly used tests for differences between groups in NLMEM, the Wald and the likelihood ratio tests (LRT), in data sets of small sample size and/or with unevenly distributed genotypes (Bertrand et al., 2008 (Bertrand et al., , 2009b . Also in the context of testing parametric against semi-parametric nonlinear mixed models, Wu and Zhang (2002) have shown that asymptotic distributions cannot be used for the Wald test and the LRT when the normality assumption of the random effects is violated, though the LRT was much less affected.
The aim of the present work is to investigate two alternatives to these asymptotic tests to detect a gene effect in PG studies: permutation and F -distribution based tests. Permutation testing is a way of determining whether the null hypothesis of randomness is reasonable, i.e.
whether the pattern present in the data could have happen by chance alone (Good, 1994; Manly, 1998) . This alternative requires fewer assumptions than a correction based on simulations from the model under the null hypothesis, but is seldom used in NLMEM (Ding and Wu, 2001) . The second alternative is to correct the Wald test for the underestimation of the variance of parameter estimates in small sample size. We investigate four such inserm-00709820, version 1 -19 Jun 2012 corrections based on F -distributions with various values of denominator degrees of freedom (df) which have been proposed in different settings.
In the present work, we study the type I error and power of these two alternatives through simulations. The permutation tests are evaluated for both the Wald and the LRT statistics whereas the F -distributions are used to correct the Wald test only. The same simulation setting as in the simulation studies mentioned before (Bertrand et al., 2008 (Bertrand et al., , 2009b was used here to enable a comparison with the results of the simulation-based correction studied in these works. As an illustration, we present an analysis of the indinavir concentration-time profiles collected in the COPHAR2 trial.
As in NLMEM the integral in the likelihood has no analytical form, estimation algorithms use model linearisation, such as the first order (FO) and first order conditional estimation with interaction (FOCE-I) (Lindstrom and Bates, 1990 ) methods implemented in the NON-MEM and the Phoenix NLME software. Others consider numerical approximations of the likelihood such as the Laplacian or Adaptive Gaussian quadrature algorithms (AGQ) or more recently stochastic approximation of the EM algorithm (SAEM) (Deylon et al., 1999) as implemented in the MONOLIX software. In Bertrand et al. (2008 Bertrand et al. ( , 2009b , we have shown that the bias in the FO algorithm leads to a very large inflation of both asymptotic tests type I error. Thus, to account for the influence of the estimation algorithm in the present work we use FOCE-I and SAEM.
In Section 2, we present the model and how the likelihood and the estimation variance matrix are obtained. Then, we introduce the usual asymptotic tests and both investigated alternatives in Section 3. In Sections 4 and 5 we describe the real data, the simulation study and the evaluation protocol. The results of the evaluation and the illustration are presented in Section 6. We finally discuss our findings and conclusions in Sections 7 and 8.
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2. Evaluation of the likelihood and the estimation variance matrix in NLMEM
Models and notation
To describe the n i -dimensional vector of concentrations y i of a subject i = 1, ..., N , we use a pharmacokinetic function f which is nonlinear in its parameters φ i :
where X i is the within-subject design vector and φ i = µ + A i β + Bη i is the subject
modelling the relationship between the covariates and φ i with β the corresponding kcoefficient effects vector. Because the covariate coefficients enter the model nonlinearly through the structural parameter associated to the covariate, the matrix-based notation peculiar to linear mixed effect models can no longer be used and therefore θ, the (p + k)-
design matrix, permitting some components of φ i to have no associated random effect when p > q. η i is the random effect q-dimensional vector which follows a Gaussian distribution with null mean and variance-covariance (q×q)-dimensional matrix Ω. ǫ i is the residual error n i -dimensional vector which follows a Gaussian distribution with null mean and variancecovariance (n i × n i )-dimensional matrix Σ i (X i ; φ i , γ) whose diagonal terms are equal to g(X i ; φ i , γ) 2 and off-diagonal terms are equal to 0.
To obtain a combination of constant and proportional error models, g(X i ; φ i , γ) can be 
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Evaluation of the likelihood
Because of the nonlinearity of the regression function in the random effects, the likelihood of NLMEM cannot be expressed in a closed form. Indeed, for the subject i, the marginal loglikelihood L i (y i ; Ψ) of Ψ for the data y i is given by
with p(y i |φ i , Ψ) the density of the observations conditioned on the random effects and the model parameters, p(φ i ; Ψ) the density of the individual parameters and p(y i ; φ i , Ψ) the likelihood of the complete data, that is,
where 
where E i and V i are respectively the marginal expectation and variance of the vector y i .
Another approach is to use an importance sampling procedure (Robert and Casella, 1983) to compute an estimate L i (y i ; Ψ) T of the observed loglikelihood, such as
where the φ i (t) are sampled from an instrumental distribution h(φ i (t) ) which is chosen to minimize the variance of the estimate L i (y i ; Ψ) T . In the MONOLIX software where such a procedure is used, the instrumental function is a non-centred Student distribution (Samson et al., 2007; Lavielle, 2008) .
Evaluation of the estimation variance matrix
The estimation variance matrix is composed of
where Var(θ) is the ((p + k) × (p + k))-estimation variance matrix for the fixed effects, Var(λ) is the (l × l)-estimation variance matrix for the variance components, and Var(θ, λ)
is the ((p + k) × l)-estimation covariance matrix between the fixed effects and the variance components. Based on the Cramer-Rao inequality, the inverse of the Fisher estimation matrix M F is the lower bound of the variance covariance matrix of any unbiased estimators of the parameters. In the framework of normal theory maximum likelihood, M F is computed as the Hessian of the loglikelihood in all the model parameters, and thus
where N is the total number of subjects. Thus, the (asymptotic) estimate of Var(Ψ) is
Here as well, linearisation of the model has been proposed to derive an approximate expression of M F . The FOCE-I approach linearises the model around the individual random effect estimatesη i (Pinheiro and Bates, 2000) .
The approximate marginal expectation E i and variance V i of the vector y i are then given by
Alternatively, a Taylor expansion of the model function f can also be performed around the individual parameter estimatesφ i =μ + A iβ +η i , which provides the following inserm-00709820, version 1 -19 Jun 2012
approximation. Then, (1) is rewritten as
which is reformulated for sake of simplicity:
. Then, the approximate marginal expectation E i and variance V i of the vectorỹ i are given by
This latter approach is implemented in the MONOLIX software.
As we need its expression in the following, let us write here the estimation variance for the fixed effects. Using a first order linearisation of the model where E i and V i are given in either (3) or (4), we have Var(θ, λ) = 0 and thus
3. Asymptotic tests and alternatives
Asymptotic tests
In asymptotic conditions, testing the null hypothesis H 0 : Cθ = 0 based on the estimates of the fixed effectsθ can be carried out with the usual Wald test, comparing the Wald statistic to the critical value of a χ 2 distribution. Here, C is a ((p + k) × U )-contrast matrix and U the number of contrasts one wishes to test. If H 0 is true, then:
H 0 can also be tested using the likelihood ratio test (LRT) that compares the models with Cθ = 0 (reduced) with the full model where θ is estimated. If H 0 is true, then:
where L reduced and L f ull are the loglikelihood of the two models.
Permutation based alternative
To perform permutation tests, R data sets are generated by permuting the rows of the covariate matrix from the original data set. For a given test, the statistic Q obs is estimated from the original data and the statistic Q perm is estimated from each of the R data sets.
Thus, r = 1, ..., R values Q permr are obtained which constitute a distribution of the statistic under the null hypothesis of no covariate effect. The permutation p-value is the proportion:
, where the operator Card(.) counts the realisations of
F -distribution based alternative
Comparing W/U to an F -distribution with an infinite denominator df is equivalent to using the classical Wald test. However, in biology studies, sample size is often small to moderate, thus approximate F -distributions with numerator df= U and non infinite denominator df have been proposed to correct for the departure from the asymptotic. In this section,we consider four different F -distribution based approaches.
The first approach derives from decomposition of the degrees of freedom in the ANOVA (Pinheiro and Bates, 2000) (=DF PB ) with a denominator df equal to
is implemented in the nlme function in R. In the second approach which is implemented in the NLMIXED Procedure in SAS, the computation of the degrees of freedom is based on the number of random effects (Wolfinger, 2000) (=DF W ) with a denominator df equal to N − q.
The third approach comes from the multivariate nonlinear models (MNLM) framework (Gallant, 1975 ) (=DF G ). In his study on nonlinear regressions contemporaneously but not serially correlated, Gallant (1975) observed that estimation variances were underestimated and thus recommended the multiplication of Var(θ) by the factor N/(N −p) and using a denominator inserm-00709820, version 1 -19 Jun 2012
df equal to N − p. In classical non linear regression, the downward bias of the maximum likelihood variance estimator is corrected using a factor of n/(n−p), with n being the number of observations and p being the number of model parameters (Huet et al., 1996) . Here, Gallant (1975) proposed substituting N and not N i=1 n i for n because MNLM, as a populationaveraged approach, focusses on the marginal expectation of the response variable (Vonesh and Chinchilli, 1997) .
The fourth approach is an extension to NLMEM of the method developed by Fai and Cornelius (1996) (=DF FC ) that is implemented in the DDFM=SATTERTH option of the MIXED Procedure in SAS. Fai and Cornelius (1996) proposed using the spectral decomposition of C ′ Var(θ)C in (6) to decompose W into a sum of U squared Student statistics with 
When U > 1, Fai and Cornelius (1996) showed that W/U follows an approximate Fdistribution with denominator df:
As, in NLMEM, Var(θ) includes derivatives, we use the following property of matrix (7) with respect to each element l of the vector λ:
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We also use this property to take the derivative of
in (8) with respect to each element l of λ, so we have, for each element q of V ech(Ω),
and for the error model parameters,
In these calculations, we linearise the model around the individual parameters estimates as described in Section 2.3.
Real Data and Simulation Study

Real data
As in our previous papers (Bertrand et al., 2008 (Bertrand et al., , 2009b , we illustrate the different approaches with data from a PK substudy of the COPHAR2-ANRS 111 study, a multicentre noncomparative pilot trial of early therapeutic drug monitoring in HIV-positive patients naïve of treatment. We focus on the PK sub-study from the group of patients receiving indinavir doses of 400, 600 and 800 mg boosted with ritonavir at a dose of 100 mg twice a day. Patients were genotyped for the exons 21 and 26 of the ABCB1 gene which code for the P-glycoprotein, and for polymorphisms on gene coding for proteins involved in the metabolism of indinavir;
the CYP 3A4*1B, CYP 3A5*3 and *6 polymorphisms.
The indinavir pharmacokinetic profiles were determined at 1, 3, 6, and 12h following drug administration, 2 weeks after the treatment onset (Fig. 1) .
[ Figure 1 about here.]
Simulation setting
An extended description of the simulations can be found in Bertrand et al. (2008) and is briefly summarised below.
Parameters from the simulated NLMEM were set based on a preliminary analysis of the indinavir data without covariates. The concentrations at time t were simulated using a one compartment model at steady state (τ = 12 h) with first order absorption (k a = 1.4 h −1 ), first order elimination (k = 0.2 h −1 ) and apparent volume of distribution (V /F = 102 L).
We use a diagonal Ω matrix and a proportional error model (g(t; φ i , γ) = bf (t, φ i )) setting the dose (D) to 400 mg. The model parameters are expressed in term of natural logarithms to achieve the positivity requirement of pharmacokinetic parameters, µ = [log(k a ) log(k) log(V /F )] ′ with random effect standard deviations set to 1.13, 0.41 and 0.26, respectively and the coefficient of variation for the residual error set to 20% (b=0.2).
We simulate a diplotype of SN P 1 and SN P 2 , with a distribution mimicking that of exons 26 and 21 of the ABCB1 gene Sakaeda et al. (2002) ; we obtained frequencies for the rare homozygotes, heterozygotes and common homozygotes of respectively 24%, 48% and 28% for SN P 1 and 29%, 44% and 27% for SN P 2 . As, in the intestine, the P-glycoprotein restricts drug entry into the body, we consider an effect on the drug bioavailability (F) through the volume of distribution V/F.
The genetic coefficient values are chosen to be consistent with results found in the literature for ABCB1 polymorphisms on drugs disposition (Marzolini et al., 2003) and provide clinically relevant effect, with V/F and CL/F (=k × V /F ) increasing from 105.4 to 200.5 L and 21.1 to 40.1 L/h respectively between common and rare homozygotes for SN P 1 .
In this work, the tests under study assess only the effect of SN P 1 on V /F even if we simulated diplotypes to allow for population genetic factors such as linkage disequilibrium.
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In the model including the covariate, the effect coefficient vector is β = [β 1 β 2 ]
′ . As we test for the effect of the SNP as a whole, we have U = 2 and C =    0 0 0 1 0
We simulated 200 data sets with N = 40 subjects and n = 4 samples as in the COPHAR2 trial under both the null hypothesis of no genetic effect (H 0 ) and the alternative hypothesis of a genetic effect (H 1 ) (Fig. 2) .
[ Figure 2 about here.]
Evaluation protocol
Simulation study
In the present research we used the FOCE-I and SAEM algorithms implemented in the softwares NONMEM version 7 and MONOLIX version 2.1 respectively to estimate the parameters, the likelihood and the estimation variance matrix. In NONMEM, the starting values were set to the simulated ones + 10% except for the standard deviation of k a which was set to 0.7. In MONOLIX, the starting values were similar for the fixed effects but the random effect standard deviations were set to 1.
For the likelihood estimation in MONOLIX, the number of iterations for the importance sampling T was set to 10000.
The alternatives proposed in the present work are evaluated in terms of type I error and 
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As described in Section 3, the type I error of the asymptotic tests is obtained using a threshold of 5.99 which is the 95 th percentile of a χ 2 distribution with 2 degrees of freedom. For the permutation test, the number R of permutations is set to 1000.
The fourth approach based on F -distribution (DF F C ) is evaluated only with SAEM in MONOLIX. Our implementation of this denominator df calculation is nested within the MONOLIX code, following the computation of the estimation variance matrix. We did not program the extension with the FOCE-I algorithm as we had no easy access to the NONMEM code dedicated to the estimation variance matrix.
Application to real data
The indinavir concentrations were analysed with the same PK model as in the simulation study, using the SAEM algorithm. The details of the covariate model building strategy are inserm-00709820, version 1 -19 Jun 2012 described in Bertrand et al. (2009a) . Briefly, we tested for demographic and biological covariates along with the genetic polymorphisms. First, a screening on the estimated individual parameters was performed, followed by a forward selection based on LRT. Then, the p-value of the covariates remaining in the final model were assessed using the asymptotic LRT as well as the four F -distribution based Wald tests for illustrative purpose.
Results
Simulation study
As shown on Table 1 , SAEM achieved convergence on all data sets and always provided the estimation variance matrix, whereas FOCE-I failed to converge and/or compute the estimation variance matrix on few data sets.
[ Table 1 about here.]
The thresholds used for the asymptotic test, the simulation based correction, and the first three F -distribution based approaches, are the same for the 200 data sets under both hypotheses. For the permutation test and the DF FC approach, the threshold comes from, respectively, the permutation based distribution and the estimated denominator df, which are both specific to the data set.
With SAEM, the type I error for the asymptotic Wald test and LRT are significantly inflated. With FOCE-I, the type I error for the asymptotic Wald test is significantly inflated whereas the asymptotic LRT estimate is at the upper limit of the prediction interval around 5%. Of note, the Wald test and LRT asymptotic estimates on the 1000 data sets used to derive the simulation-based threshold are 8.9% and 7.6% with SAEM and 12.2% and 7.4% As displayed on Fig. 3 , all the Kolmogorov distance estimates are below the K-S threshold for the permutation test and the simulation based correction. With SAEM and FOCE-I, the Kolmogorov distance estimate of the DF G approach is similar to that obtained using permutation test or simulations based correction with both estimation algorithms, although the type I error estimate is about 10% with FOCE-I and not significantly different from the nominal level of 5% with SAEM. For the asymptotic test and the DF PB approach, the Kolmogorov distance and type I error estimates are close and significantly inflated. Indeed, the large denominator df of the DF PB approach leads to a threshold quite close to that of a χ 2 divided by 2. The DF FC and the DF W methods also have close and significantly inflated estimates of Kolmogorov distance and type I error, though lower than the asymptotic test.
The range of denominator df obtained with the DF FC method is quite narrow and happens to include that of the DF W approach. Fig. 4 shows that for the Wald test with SAEM, one should use a denominator df of 10 to obtain a type I error of exactly 5%, and between 6 and 27 for an estimate non significantly different from 5%.
[ using the DF P B approach, 0.018 and 0.048 using the DF W approach, 0.023 and 0.057 using the DF G approach, and 0.02 and 0.047 using the DF F C approach.
Only the effect of the CYP 3A4*1B polymorphism remains in the final model, as the effect of age is discarded based on the p-value estimates from the permutation test and the DF G approach.
Discussion
Several studies have evaluated by simulation the performance of tests for discrete covariate on continuous responses using NLMEM with various designs and estimation methods (see the review in the discussion of Bertrand et al. (2009b) ). Permutation tests and F -distribution based tests have been compared in the linear mixed effects framework (Lin and Heagerty, 2004; Routledge, 1997) . In particular Routledge (1997) Manly (1998) argues however that it is equivalent to question the representativeness of the study sample which also conditions the external validity of classical tests.
Because the covariates enter the model in a linear fashion, we also consider using a F -distribution for the Wald test, a widely used method in LMEM (Verbeke and Molenberghs, 1997). The df of the DF PB approach which is derived from the multivariate ANOVA differs greatly from the df used within the mixed effect framework. Indeed, in the multivariate ANOVA, the subject concentrations are considered as independent variables under the influence of the genotype and the multivariate statistic is based on the comparison of the between and within variance matrices whose covariance terms inform on the correlation between the variables. Thus in this approach, n variables are considered in N subjects leading to an N × n sample size. Then, one degree of freedom is subtracted per parameter estimates minus the number of contrast tested. On the other hand in the mixed effects model, the independent variable is the subject with N the sample size. For DF W and DF G , one degree of freedom is subtracted per inserm-00709820, version 1 -19 Jun 2012 random effect variance and fixed effect respectively. For DF FC , the information available in the data for the parameter estimation is quantified through the variance of parameter estimates rather than by subtracting degrees of freedom to the sample size. Here, all these methods however fail to correct for the Wald type I error inflation, as the denominator df estimates for the 200 data sets are too large. Actually, the optimal denominator df is even smaller than the number of independent observations to compensate for the downward bias of the variance of the estimates, as shown by the performance of the DF G method.
Indeed, the only method based on an F -distribution that corrects for the type I error inflation of the Wald test is the DF G method with SAEM. With the FOCE-I algorithm, the Kolmogorov distance suggested an improvement using the DF G method despite the fact that we observed an inflation of the type I error, indicating that the correction may be useful even in this case. To go past the simple design under study here, we considered two other designs from a previous study evaluating the Wald test and the LRT (Bertrand et al., 2009b ): a design optimised using the PFIM software (Retout et al., 2007) including N = 80 subjects sorted in 4 groups with n = 2 samples and a combined design with N = 20 subjects having n = 4 samples plus N = 80 subjects with only one trough concentration (n = 1). The type I error estimates using the classical Wald test and the DF G method are 8.7% and 5.7%, respectively for the optimal design and 8.4% and 4.5%, respectively for the combined design.
These results show that the DF G method also corrects the type I error inflation observed in these designs. However, it does so not only through approximating the distribution for the Wald test but essentially through inflating the estimation variance for the effect coefficient by the factor N/(N − p). This factor, which brings Bessel's correction for the unbiased estimator of the variance to mind, was recommended by Gallant (1975) One limitation of the present research is that we consider the method developed by Fai and Cornelius (1996) and not the method developed by Kenward and Roger (1997) . 
Conclusion
While this research confirms the feasibility of permutation tests in pharmacogenetic studies for both the LRT and the Wald test, further investigations in other simulation settings are required to recommend the F -distribution based approach proposed in multivariate nonlinear models for the Wald test. As permutation does only slightly better than the asymptotic alternatives for an additional computing burden, a sensible course of action could be to use it only when decisions based respectively on the asymptotic test and the Gallant alternative are discordant. Table 1 Threshold, denominator degrees of freedom (df ), type I error, and power estimates (%) of the Wald test and the LRT for different approaches, using both FOCE-I and SAEM
